BloombergLean L·
Novartis Inks Chinese mRNA-Therapy Deal for Up to $7.8 Billion
Novartis AG will license a messenger RNA-based autoimmune therapy from China’s Abogen Biosciences, in a deal worth as much as $7.8 billion.
Read at Bloomberg →
Novartis AG will license a messenger RNA-based autoimmune therapy from China’s Abogen Biosciences, in a deal worth as much as $7.8 billion.
<iframe src="https://statesidedaily.com/embed/cluster/ff69bfb374b7601e76fed15ae79b39c101c68bcd" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Novartis Inks Chinese mRNA-Therapy Deal for Up to $7.8 Billion"></iframe>